Browsing by Author "Ozguroglu, M."
Now showing 1 - 12 of 12
- Results Per Page
- Sort Options
Item Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+NSCLC: Primary Analysis from JAVELIN Lung 100(2022) Reck, M.; Barlesi, F.; Yang, , J. C.-H.; Westeel, V.; Felip, E.; Ozguroglu, M.; Dols, M. Cobo; Sullivan, R.; Kowalski, D.; Andric, Z.; Lee, D. H.; Sezer, A.; Shamrai, V.; Szalai, Z.; Wang, X.; Xiong, H.; Jacob, N.; Mehr, K. Tadjalli; Park, K.Item Cemiplimab for Advanced Non-Small Cell Lung Cancer: Squamous Subgroup Analysis for EMPOWER-Lung 1 And 3(2023) Makharadze, T.; Gogishvili, M.; Melkadze, T.; Baramidze, A.; Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Penkov, K. D.; Giorgadze, D.; Ozguroglu, M.; Kalinka, E.; McIntyre, D.; Kaul, M.; Quek, R. G. W.; Pouliot, J-F.; Seebach, F.; Gullo, G.; Rietschel, P.Item Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Makharadze, T.; Paydas, S.; Nechaeva, M.; Seebach, F.; Weinreich, D.M.; Yancopoulos, G.D.; Gullo, G.; Lowy, I.; Rietschel, P.Item Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1(2023) Gumus, M.; Kilickap, S.; Sezer, A.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R. G.Item EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%(2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvilli, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; 0000-0002-6445-1439; AAD-2667-2020Item EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%(2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; 0000-0002-6445-1439; AAD-2667-2020Item Patient-Reported Outcomes (Pros) Of Cemiplimab Vs Chemotherapy In Advanced Non-Small Cell Lung Cancer (Ansclc): EMPOWER-Lung 1 Histology Subgroups(2022) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R.Item Patient-Reported Outcomes (Pros) With First-Line (1L) Cemiplimab In Patients With Locally Advanced Non-Small Cell Lung Cancer (Lansclc): EMPOWER-Lung 1 Subpopulation(2022) Bondarenko, I.; Sezer, A.; Kilickap, S.; Gumus, M.; Ozguroglu, M.; Gogishvili, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R. G.Item Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1(2022) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R. G.Item Patient-Reported Outcomes with Cemiplimab Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer (Ansclc): Geographic Region Subgroups in EMPOWER-Lung 1(2022) Ho, G. F.; Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R. G.Item Phase I/II Study of Spartalizumab (PDR001), An Anti-PD1 Mab, in Patients with Advanced Melanoma or Non-Small Cell Lung Cancer(2018) Lin, C-C.; Taylor, M.; Boni, V.; Brunsvig, P. F.; Geater, S. L.; Salvagni, S.; Garrido Lopez, P.; Ozguroglu, M.; Sriuranpong, V.; Ponce Aix, S.; Ascierto, P. A.; Fasolo, A.; Sezer, A.; Kowalski, D. M.; Faris, J. E.; Cameron, S.; Mataraza, J.; Wu, H.; Antona, V.; Ochoa de Olza, M.Item Three Years Survival Outcome And Continued Cemiplimab (CEMI) Beyond Progression With The Addition Of Chemotherapy (Chemo) For Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): The EMPOWER-Lung 1 Trial(2022) Ozguroglu, M.; Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.; Nechaeva, M.; Schenker, M.; Cicin, I.; Ho, G. F.; Kulyaba, Y.; Dvorkin, M.; Zyuhal, K.; Scheusan, R. I.; Li, S.; Pouliot, J-F.; Seebach, F.; Lowy, I.; Gullo, G.; Rietschel, P.